Abstracts Archive - Page 2422 of 2607 - ACR Meeting Abstracts

Abstract Number: 64 • 2013 ACR/ARHP Annual Meeting
Fibulin-3 In Joint Aging and Osteoarthritis Pathogenesis
Akihiko Hasegawa^1,2, Tomo Yonezawa¹, Noboru Taniguchi¹, Koji Otabe¹, Yukio Akasaki¹, Tetsuya Matsukawa¹, Masahiko Saito³, Masashi Neo⁴, Lihua Y. Marmorstein⁵ and Martin K. Lotz¹, ¹Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ²Orthopaedic Surgery, Osaka Medical College, Takatsuki, Osaka, Japan, ³Orthopaedic Surgery, Toho University Sakura Medical Center, Sakura, Japan, ⁴Department of Orthopedic Surgery, Osaka Medical College, Osaka, Japan, ⁵Department of Ophthalmology and Vision Science, University of Arizona, Tucson, AZ
Background/Purpose: Osteoarthritis (OA) is the most common joint disease. Among the earliest lesions during OA development is disruption of the superficial zone (SZ) of articular…
Abstract Number: 65 • 2013 ACR/ARHP Annual Meeting
The Frequency Of Bone Marrow Oedema Adjacent To The Cruciate Ligament Peri-Entheseal Vascular Channels In Inflammatory and Degenerative Arthritis
Daniel Binks^1,2, Melissa Matzelle³, Diane Bergin⁴, Richard J. Hodgson^2,5, Ai Lyn Tan^1,2, Ellen M. Gravallese⁶, Dennis McGonagle^1,2,7 and Aleksandra Radjenovic^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA, ⁴Radiology, Galway University Hospitals, Galway, Ireland, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: We noted in mouse models of inflammatory arthritis (IA) that an early point of entry of inflammation into the marrow space occurred at sites…
Abstract Number: 66 • 2013 ACR/ARHP Annual Meeting
Follistatin-Like Protein 1 Is An Important Regulator Of Chondrogenesis
Yury Chaly¹, Sonja Smith², Daniel Bushnell³, Brian Campfield⁴, Harry Blair⁵ and Raphael Hirsch⁶, ¹Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, ²University of Iowa Carver College of Medicine, Iowa City, IA, ³Division of Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁴Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁵University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Department of Pediatrics,, University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Chondrocytes play a pivotal role in osteoarthritis (OA) because they are the only cells in the articular cartilage that are responsible for maintenance of…
Abstract Number: 68 • 2013 ACR/ARHP Annual Meeting
Autophagy Activation Protects From Mitochondrial Dysfunction In Human Chondrocytes
Beatriz Caramés¹, Paloma López de Figueroa², Martin Lotz³ and Francisco J. Blanco⁴, ¹Osteoarticular and Aging Research Lab, INIBIC–Complejo Hospitalario Universitario A Coruña, SPAIN, A Coruña, Spain, ²Cartilage Biology group. Rheumatology Division, INIBIC-A Coruña, Spain, A Coruña, Spain, ³The Scripps Research Institute, La Jolla, USA, La Jolla, CA, ⁴Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain
Background/Purpose: A common feature of aging-related diseases, such as osteoarthritis (OA), is the progressive accumulation of damaged macromolecules leading to cell dysfunction and death. Autophagy,…
Abstract Number: 75 • 2013 ACR/ARHP Annual Meeting
Decorin-Deficiency Alters Cartilage Stiffness and Attenuates The Development Of Osteoarthritis In Mice
Tobias Gronau¹, Uwe Hansen², Daniela Seidler², Renato Iozzo³, Attila Aszodi⁴, Carina Prein⁵, Hauke Clausen-Schaumann⁵, Karsten Krüger⁶, Frank Mooren⁶, Jessica Bertrand¹, Thomas Pap⁷, Peter Bruckner² and Rita Dreier², ¹Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany, ²Institute for Physiological Chemistry & Pathobiochemistry, University Hospital Münster, Münster, Germany, ³Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, ⁴Experimental Surgery and Regenerative Medicine, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Department of Applied Sciences and Mechatronics, Munich University of Applied Sciences, Munich, Germany, ⁶Institute of Sports Medicine, Justus-Liebig University Giessen, Giessen, Germany, ⁷Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: In articular (AC) and growth plate (GP) cartilage, the small leucine-rich proteoglycan decorin is mainly present within the interterritorial regions (ITs) of the extracellular…
Abstract Number: 76 • 2013 ACR/ARHP Annual Meeting
Protective Effect Of Intra-Articular Injection Of Alginate-Chitosan Beads In An Hydrogel Against The Development Of Experimental Osteoarthritis Lesions In Rabbit
Frédéric Oprenyeszk¹, Mickael Chausson², Véronique Maquet², Jean-Emile Dubuc³ and Yves Henrotin¹, ¹University of Liège, Bone and Cartilage Research Unit, Liège, Belgium, ²Parc industriel des Haut-Sarts, KitoZyme SA, Herstal, Belgium, ³Clinical University Saint Luc, Orthopaedic Department, Bruxelles, Belgium
Background/Purpose: Today, there is no treatment to cure osteoarthritis (OA) or to delay effectively its progression. Current treatments are mainly based on the alleviation of…
Abstract Number: 77 • 2013 ACR/ARHP Annual Meeting
Human Mesenchymal Stem Cells Cultured On Collagen Scaffolds For Cartilage Tissue Engineering
Clara Sanjurjo-Rodríguez¹, Adela Helvia Martínez-Sánchez², Tamara Hermida-Gómez¹, Isaac M. Fuentes-Boquete^1,2, Francisco J. De Toro^2,3, Julia Buján⁴, Silvia Díaz-Prado^2,3 and Francisco J. Blanco², ¹Grupo de Bioingeniería Tisular y Terapia Celular (CBTTC-CHUAC). CIBER-BBN/ISCIII. Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de Coruña (CHUAC). SERGAS. Universidade de A Coruña, A Coruña, Spain, ²Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain, ³INIBIC-Universidade da Coruña, A Coruña, Spain, ⁴University of Alcalá de Henares, Department of Medical Specialties, Madrid, Spain
Background/Purpose: Osteoarthritis is a degenerative disease without a treatment. Tissue Engineering could provide an alternative tool for cartilage repair. The aim of this study was…
Abstract Number: 78 • 2013 ACR/ARHP Annual Meeting
Norepinephrine (NE) Inhibits Mesenchymal Stem Cell (MSCs) Chondrogenesis By Accelerating Hypertophy – Relevance For Cartilage Regeneration
Zsuzsa Jenei-Lanzl¹, Peter Angele², Frieder Kees³, Georg Pongratz⁴ and Rainer H. Straub⁵, ¹Department of Internal Medicine, University Hospital Regensburg, 1Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Regensburg, Germany, ²Department of Trauma Surgery, University Hospital Regensburg, Germany, Regensburg, Germany, ³Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany, ⁴Internal Medicine, University Hospital Regensburg, Regensburg, Germany, ⁵Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany
Background/Purpose: The high potential of mesenchymal stem cells (MSCs) in cartilage regeneration is undoubtful. The presence of MSCs in healthy or arthritic cartilage has also…
Abstract Number: 79 • 2013 ACR/ARHP Annual Meeting
Synovial Activation In Experimental OA Drives Immuno suppressive Effects Of Adipose-derived Stem Cells After Local Administration and Protects Against Chondrogenesis In Ligaments
Peter L.E.M. van Lent¹, Rik Schelbergen¹, Menno C. ter Huurne², Arjen B. Blom¹, Johannes Roth³, Thomas Vogl⁴, Christian Jorgensen⁵ and Wim B. van den Berg⁶, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁴Institute of Immunology, University of Muenster, Muenster, Germany, ⁵Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ⁶Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: A substantial subpopulation of patients with early osteoarthritis (OA) show a thickened synovial lining layer comprising macrophages expressing an activated phenotype (reflected by production of…
Abstract Number: 39 • 2013 ACR/ARHP Annual Meeting
Chaperone-Mediated Autophagy As a Target Of Therapeutic P140 Peptide Used In Lupus
Sylviane Muller, Institut de Biologie Moléculaire et Cellulaire, CNRS, Strasbourg, France
Background/Purpose: In the pipeline of molecules with a potential for treating lupus patients, the P140 peptide/Lupuzor holds a lot of promise. P140 is a 21-mer…
Abstract Number: 53 • 2013 ACR/ARHP Annual Meeting
Adenosine A_2A Receptor As a Potential New Therapeutic Target For The Prevention/Treatment Of Osteoarthritis
Aranzazu Mediero¹, Tuere Wilder² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, ³Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Osteoarthritis, the most common type of arthritis in the United States, results from trauma and other mechanical factors as well as metabolic changes in…
Abstract Number: 59 • 2013 ACR/ARHP Annual Meeting
Downregulated Forkhead-Box Class O Transcription Factors Attenuate Oxidative Stress Resistance In Human Chondrocytes
Yukio Akasaki and Martin K. Lotz, Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
Background/Purpose: Aging-associated changes in articular chondrocytes represent a major risk factor for osteoarthritis (OA). The major signaling pathway that regulates cellular aging is the Insulin/IGF-1/Pl3k/Akt/forkhead-box…
Abstract Number: 58 • 2013 ACR/ARHP Annual Meeting
Saturated Fatty Acids Act Synergistically With Interleukin 1 Beta To Increase Inflammation, Endoplasmic Reticulum Stress and Cell Death In Human Articular Chondrocytes
Oscar Alvarez-Garcia¹, Nicole H Rogers², Roy G Smith³ and Martin K. Lotz¹, ¹Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ²California Institute for Biomedical Research (Calibr), La Jolla, CA, ³Department of Metabolism and Aging, Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL
Background/Purpose: Obesity is a major risk factor for the development of osteoarthritis (OA). Altered biomechanics have been postulated as the main causative mechanism, but recent…
Abstract Number: 40 • 2013 ACR/ARHP Annual Meeting
Preclinical Characterization Of a Humanized Antagonistic Anti-CD40 Mab
Kerry Ralph, Amy Nicoletti, Eunice Musvasva, Susan Cannan, Susan VanTongeren, Diann Blanset, Scott Brodeur, Jennifer Ahlberg, Hua Li, Steve Fogal, Sudha Desai, Kathy O'Shea, Rachel Kroe-Barrett, Gerald Nabozny, Helen Wu, Gale Hansen, Keith Canada, Sanjaya Singh, Meera Ramanujam and Christine Grimaldi, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: CD40-CD40L interactions play a central role in T-B cell costimulation. Targeting this pathway has generated great interest; however early attempts to target CD40L failed…
Abstract Number: 41 • 2013 ACR/ARHP Annual Meeting
Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity
Peter Schafer¹, Emily Rychak², Derek Mendy³, Stacey Parton¹, Lori Capone⁴, Antonia Lopez-Girona², Dorota Cedzik⁵, Jolanta Kosek⁵, Ling-Hua Zhang⁵ and Rajesh Chopra⁵, ¹Department of Translational Development, Celgene Corporation, Summit, NJ, ²Molecular & Medical Science, Celgene Signal Research, San Diego, CA, ³Celgene Signal Research, San Diego, CA, ⁴Celgene Corporation, Summit, NJ, ⁵Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex including CUL4A, DDB1, and ROC-1. CC-220 is a novel immunomodulatory compound currently in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].